CN109077999A - A kind of long-acting slow-release Tilmicosin injection and preparation method thereof - Google Patents
A kind of long-acting slow-release Tilmicosin injection and preparation method thereof Download PDFInfo
- Publication number
- CN109077999A CN109077999A CN201811012891.7A CN201811012891A CN109077999A CN 109077999 A CN109077999 A CN 109077999A CN 201811012891 A CN201811012891 A CN 201811012891A CN 109077999 A CN109077999 A CN 109077999A
- Authority
- CN
- China
- Prior art keywords
- injection
- tilmicosin
- oil
- long
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002347 injection Methods 0.000 title claims abstract description 41
- 239000007924 injection Substances 0.000 title claims abstract description 41
- JTSDBFGMPLKDCD-XVFHVFLVSA-N tilmicosin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O JTSDBFGMPLKDCD-XVFHVFLVSA-N 0.000 title claims abstract description 36
- 229960000223 tilmicosin Drugs 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 24
- 239000003921 oil Substances 0.000 claims abstract description 18
- 235000019198 oils Nutrition 0.000 claims abstract description 18
- 239000003960 organic solvent Substances 0.000 claims abstract description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 12
- 239000002904 solvent Substances 0.000 claims abstract description 7
- 239000003549 soybean oil Substances 0.000 claims abstract description 6
- 235000012424 soybean oil Nutrition 0.000 claims abstract description 6
- 239000002285 corn oil Substances 0.000 claims abstract description 4
- 235000005687 corn oil Nutrition 0.000 claims abstract description 4
- 239000004519 grease Substances 0.000 claims abstract description 4
- 238000003556 assay Methods 0.000 claims description 4
- 229940074076 glycerol formal Drugs 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 238000005660 chlorination reaction Methods 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 7
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 231100000567 intoxicating Toxicity 0.000 abstract description 2
- 230000002673 intoxicating effect Effects 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 231100000518 lethal Toxicity 0.000 description 10
- 230000001665 lethal effect Effects 0.000 description 10
- 241000282898 Sus scrofa Species 0.000 description 8
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 241000283073 Equus caballus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229930194936 Tylosin Natural products 0.000 description 1
- 239000004182 Tylosin Substances 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- -1 phosphatide Chemical compound 0.000 description 1
- 201000006509 pleuropneumonia Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- 229960004059 tylosin Drugs 0.000 description 1
- 235000019375 tylosin Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Dispersion Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Pregnancy & Childbirth (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a kind of long-acting slow-release Tilmicosin injection, including Tilmicosin 300g, organic solvent 100-500ml, injection oil 200-500mlg, cholesterol 0.1g, phosphatidase 0 .5g, the organic solvent includes acetone, chloroform, carbon tetrachloride, the solvent of Tilmicosin can be mixed and can dissolved with grease, and the injection oil is injection soybean oil, injection corn oil, rilanit special.The beneficial effects of the present invention are: prior art effective dose on pig uses the generation that can cause intoxicating phenomenon, the present invention uses a kind of long-acting slow-release technology, the residence time of drug in blood can be extended, extend the action time of drug, it is absorbed Tilmicosin slowly, is unlikely to so that drug is absorbed in the short time and is poisoned.
Description
Technical field
The present invention relates to a kind of long-acting slow-release Tilmicosin injections and preparation method thereof.
Background technique
Tilmicosin is by a kind of dedicated antibiotic of the semi-synthetic livestock and poultry of hydrolysate of tylosin, is 80 years 20th century
The semi-synthetic dedicated antibiotic of macrolides livestock and poultry of generation exploitation is mainly used for preventing and treating domestic animal pneumonia (by pleuropneumonia unwrapping wire bar
Bacterium, Pasteurella, mycoplasma infection cause), the mazoitis of avian mycoplasmas disease and lactating mammal.
Tilmicosin injection is larger to cardiac toxic at present, especially applies on pig, and Tilmicosin is to Pigs Hearts dysentery
Property larger obtained using intramuscular injection 10mg/kg weight, that is, the poisoning such as compact breathing, vomiting occur and faint from fear using conclusion
Symptom, but be unlikely to cause death, using 15mg/kg weight, critical case is dead quickly, uses 30mg/kg to general case
Weight can cause death in 15 minutes, and the death rate is up to 80%.It is i.e. lethal that ox is once injected intravenously 5mg/kg.Ox subcutaneous injection
50mg/kg can cause myocardium toxicity, and 150mg/kg can be lethal, and pig, primate and horse intravenous injection also have lethal dangerous.
Summary of the invention
Effective dose is using the generation that can cause intoxicating phenomenon on pig for the prior art, and the present invention is using a kind of long-acting slow-release
Technology can extend the residence time of drug in blood, extend the action time of drug, be absorbed Tilmicosin slowly, no
It is poisoned as drug is absorbed in the short time.
Technical solution: a kind of long-acting slow-release Tilmicosin injection, including Tilmicosin 300g, organic solvent 100-
500ml, injection oil 200-500mlg, cholesterol 0.1g, phosphatidase 0 .5g, the organic solvent includes acetone, chloroform, four chlorinations
Carbon, can mix with grease and can dissolve the solvent of Tilmicosin, the injection oil be injection soybean oil, injection corn oil,
Rilanit special.
Further, the Tilmicosin 300g, organic solvent 100-500ml, injection oil 200-500mlg, cholesterol
0.1g, phosphatidase 0 .5g, dissolved total amount are 1000ml.
It further, further include glycerol formal.
The invention further relates to a kind of preparation method of long-acting slow-release Tilmicosin injection, liposome technology is applied to this hair
In bright, carrier is done with oil-based solvent, takes organic solvent, Tilmicosin, phosphatide, cholesterol is added and is allowed to dissolve, injection is added
Oily constant volume.Filtering encapsulating after detection is qualified, 100 degrees Celsius of sterilizing 30 minutes.
Compared with the prior art, the present invention has the following advantages:
The scope of application and dosage of the Tilmicosin injection of the prior art and adverse reaction are as follows:
[usage and dosage] subcutaneous injection: ox, every 1kg weight 0.033ml.Only inject 1 time.
[adverse reaction] this product is mainly cardiovascular system to the toxic effect of animal, can cause tachycardia and convergent force
Weaken.It is i.e. lethal that ox is once injected intravenously 5mg/kg.Pig, primate and horse intravenous injection also have lethal dangerous.Ox-hide
Lower injection 50mg/kg can cause myocardium toxicity, and 150mg/kg can be lethal.
The scope of application, usage and dosage and adverse reaction (through using result to obtain) of the invention:
[usage and dosage] subcutaneous injection: ox, every 1kg weight 0.05ml.Pig per kilogram of body weight 0.06ml is only injected 1 time.
[adverse reaction] this product is mainly cardiovascular system to the toxic effect of animal, can cause tachycardia and convergent force
Weaken.It is i.e. lethal that ox is once injected intravenously 5mg/kg.Pig, primate and horse intravenous injection also have lethal dangerous.Ox-hide
Lower injection 100mg/kg can cause myocardium toxicity, and 200mg/kg can be lethal.Pig subcutaneous injection 100mg/kg can cause myocardium toxicity,
200mg/kg can be lethal.
The two compares, and the principle of slow-absorbing of the present invention emerges from out, dosage can increase on the basis of original and
The risk of medication poisoning is not increased, and the present invention applies on pig and also solves the problems, such as easily to be poisoned, and can be widely applied.
Specific embodiment
Tilmicosin injection of the present invention, it includes the following component of 1000ml, Tilmicosin 300g, organic solvent 100-
500ml, injection oil 200-500mlg, cholesterol 0.1g, phosphatidase 0 .5g.
Heretofore described organic solvent includes that acetone, chloroform, carbon tetrachloride etc. can mix with grease and can dissolve and replace
The solvent of meter Kao Xing.Qs glycerin formal can also be added and improve dissolution rate.The injection oil is injection soybean oil, injection
Corn oil, rilanit special etc..
The preparation method of Tilmicosin injection of the invention, liposome technology are applied in the present invention, use oil-based solvent
Carrier is done, takes organic solvent appropriate, Tilmicosin, phosphatide, cholesterol is added and is allowed to dissolve, oil for injection constant volume is added.Detection
Filtering encapsulating after qualified, 100 degrees Celsius of sterilizing 30 minutes to get.
Embodiment 1:
Chloroform 500ml is taken, Tilmicosin 300g, phosphatidase 0 .5g, cholesterol 0.1g is added and is allowed to be completely dissolved, injection oil is added extremely
1000ml filters encapsulating after the assay was approved, and 100 degrees Celsius sterilize for 30 minutes to obtain the final product.
Embodiment 2:
It takes acetone 400ml, glycerol formal 100ml after mixing, Tilmicosin 300g, phosphatidase 0 .5g, cholesterol is added
0.1g heating is allowed to dissolve, and soybean oil is added to 1000ml, filters encapsulating after the assay was approved, 100 degrees Celsius of sterilizings in 30 minutes are
?.
Basic principles and main features and advantages of the present invention of the invention have been shown and described above.The skill of the industry
Art personnel should be recognized that.The present invention is not limited by examples detailed above, and original of the invention is only illustrated in examples detailed above and specification
Reason, various changes and improvements may be made to the invention under the premise without departing from the spirit and scope of the present invention, these change and change
Into all fall within the protetion scope of the claimed invention, the claimed scope of the invention is by appended claims and its equivalent
Object defines.
Claims (6)
1. a kind of long-acting slow-release Tilmicosin injection, it is characterised in that: including Tilmicosin 300g, organic solvent 100-
500ml, injection oil 200-500mlg, cholesterol 0.1g, phosphatidase 0 .5g, the organic solvent includes acetone, chloroform, four chlorinations
Carbon, can mix with grease and can dissolve the solvent of Tilmicosin, the injection oil be injection soybean oil, injection corn oil,
Rilanit special.
2. a kind of long-acting slow-release Tilmicosin injection according to claim 1, it is characterised in that: the Tilmicosin
300g, organic solvent 100-500ml, injection oil 200-500mlg, cholesterol 0.1g, phosphatidase 0 .5g, dissolved total amount are
1000ml。
3. a kind of long-acting slow-release Tilmicosin injection according to claim 1 or 2, which is characterized in that further include glycerol
Formal.
4. a kind of preparation method of long-acting slow-release Tilmicosin injection, it is characterised in that: liposome technology is applied to the present invention
In, carrier is done with oil-based solvent, takes organic solvent, Tilmicosin 300g, phosphatidase 0 .5g, cholesterol 0.1g is added and is allowed to dissolve,
Be added and inject oily constant volume, detect it is qualified after filtering encapsulating, 100 degrees Celsius of sterilizing 30 minutes.
5. a kind of preparation method of long-acting slow-release Tilmicosin injection according to claim 4, it is characterised in that: described
Organic solvent be chloroform 500ml, Tilmicosin 300g is added, phosphatidase 0 .5g, cholesterol 0.1g are allowed to be completely dissolved, note is added
It penetrates after oil dissolution to 1000ml, filters encapsulating after the assay was approved, 100 degrees Celsius sterilize for 30 minutes to obtain the final product.
6. a kind of preparation method of long-acting slow-release Tilmicosin injection according to claim 4, it is characterised in that: described
Organic solvent be acetone 400ml, glycerol formal 100ml mixture, it is solid that Tilmicosin 300g, phosphatidase 0 .5g, gallbladder is added
Alcohol 0.1g heating is allowed to dissolve, and injection oil 1000ml is added, and the injection oil is soybean oil, filters encapsulating after the assay was approved,
100 degrees Celsius sterilize for 30 minutes to obtain the final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811012891.7A CN109077999A (en) | 2018-08-31 | 2018-08-31 | A kind of long-acting slow-release Tilmicosin injection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811012891.7A CN109077999A (en) | 2018-08-31 | 2018-08-31 | A kind of long-acting slow-release Tilmicosin injection and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109077999A true CN109077999A (en) | 2018-12-25 |
Family
ID=64840314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811012891.7A Pending CN109077999A (en) | 2018-08-31 | 2018-08-31 | A kind of long-acting slow-release Tilmicosin injection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109077999A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108392467A (en) * | 2018-05-30 | 2018-08-14 | 山东德信生物科技有限公司 | A kind of Tilmicosin injection and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005025488A2 (en) * | 2003-08-27 | 2005-03-24 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
| CN101249069A (en) * | 2008-03-27 | 2008-08-27 | 孙卫 | Tilmicosin long-acting injection and method of preparing the same |
| CN101416978A (en) * | 2007-10-22 | 2009-04-29 | 洛阳普莱柯生物工程有限公司 | Preparation method of tilmicosin long-acting injection |
| US20110098266A1 (en) * | 2002-03-21 | 2011-04-28 | Pharmacia & Upjohn Company Llc | Method of administering an injectable antibiotic to an animal |
| CN108368079A (en) * | 2015-12-02 | 2018-08-03 | 优拓制药公司 | Treat the compound and method of bacterium infection |
| CN108392467A (en) * | 2018-05-30 | 2018-08-14 | 山东德信生物科技有限公司 | A kind of Tilmicosin injection and preparation method thereof |
-
2018
- 2018-08-31 CN CN201811012891.7A patent/CN109077999A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110098266A1 (en) * | 2002-03-21 | 2011-04-28 | Pharmacia & Upjohn Company Llc | Method of administering an injectable antibiotic to an animal |
| US20150182454A1 (en) * | 2002-03-21 | 2015-07-02 | Zoetis P&U Llc | Method of administering an injectable antibiotic to an animal |
| WO2005025488A2 (en) * | 2003-08-27 | 2005-03-24 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
| CN101416978A (en) * | 2007-10-22 | 2009-04-29 | 洛阳普莱柯生物工程有限公司 | Preparation method of tilmicosin long-acting injection |
| CN101249069A (en) * | 2008-03-27 | 2008-08-27 | 孙卫 | Tilmicosin long-acting injection and method of preparing the same |
| CN108368079A (en) * | 2015-12-02 | 2018-08-03 | 优拓制药公司 | Treat the compound and method of bacterium infection |
| CN108392467A (en) * | 2018-05-30 | 2018-08-14 | 山东德信生物科技有限公司 | A kind of Tilmicosin injection and preparation method thereof |
Non-Patent Citations (6)
| Title |
|---|
| 全国中医药专业技术资格考试大纲与细则编委会: "《2016全国中医药专业技术资格考试大纲与细则》", 30 December 2015 * |
| 周浩: "替米考星长效注射液的研制", 《中国优秀硕士学位论文全文数据库》 * |
| 安电进等: "替米考星注射液对牛呼吸道巴氏杆菌感染的治疗", 《中国兽医杂志》 * |
| 李向辉等: "替米考星纳米乳的制备及其质量评价", 《西北农林科技大学学报(自然科学版)》 * |
| 王春燕: "《药剂学》", 30 September 2017 * |
| 胡功政: "《新全实用兽药手册》", 30 September 2009, 河南科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108392467A (en) * | 2018-05-30 | 2018-08-14 | 山东德信生物科技有限公司 | A kind of Tilmicosin injection and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rogstad et al. | Pharmacokinetics and bioavailability of flumequine and oxolinic acid after various routes of administration to Atlantic salmon in seawater | |
| AU2016258642B2 (en) | Cabazitaxel fat emulsion injection, and preparation method and use thereof | |
| EP2832349B1 (en) | Lactate-based fulvestrant or fulvestrant derivative oily preparation and preparation method thereof | |
| Ling et al. | Comparative antiallodynic activity of morphine, pregabalin and lidocaine in a rat model of neuropathic pain produced by one oxaliplatin injection | |
| RS60558B1 (en) | Pentaaza macrocyclic ring complexes possessing oral bioavailability | |
| CN109077999A (en) | A kind of long-acting slow-release Tilmicosin injection and preparation method thereof | |
| CN102961368B (en) | Curcumin nanosuspension and preparation method thereof | |
| CN102429918A (en) | Pharmaceutical composition containing florfenicol and tea saponin and preparation method thereof | |
| CN108392467A (en) | A kind of Tilmicosin injection and preparation method thereof | |
| CN104095871A (en) | Veterinary injection containing lincomycin hydrochloride and spectinomycin sulfate | |
| DE2608079A1 (en) | DRUG PREPARATION IN THE FORM OF A DRY PREPARATION FOR THE PREPARATION OF INJECTIONS | |
| Marchenko et al. | Efficacy of novel formulations of ivermectin and albendazole in parasitic infections of sheep in the Altai mountains of Russia | |
| CN102697725B (en) | Veterinary ciprofloxacin lactate injection and preparation method thereof | |
| CN103860579B (en) | A kind of compound tilmicosin injection liquid and its preparation method | |
| Nonaka et al. | Pretreatment with lidocaine accelerates onset of vecuronium-induced neuromuscular blockade | |
| CN103230583A (en) | Veterinary niacin norfloxacin compound injection for treating intestinal diseases and preparation method | |
| CN108815168B (en) | Nano-emulsion preparation for resisting bacterial infection and preparation method and application thereof | |
| CN105125484A (en) | Painless doxycycline injection and preparation method thereof | |
| CN104095815A (en) | Preparation method for tulathromycin emulsifable injection | |
| CN104606195B (en) | A kind of compound herba fibraureae recisea injection and preparation method thereof | |
| CN104292226A (en) | Paliperidone amino acid derivatives and application thereof | |
| CN101361709B (en) | 0Long-acting enrofloxacin injection and preparation method thereof | |
| CN102258467A (en) | Formula and preparation of intravenous injection sustained-release fat emulsion of arteannuin and derivative thereof | |
| CN101933901A (en) | A kind of suspension injection containing tylosin and preparation method thereof | |
| CN101883563A (en) | Injection comprising docetaxel and its preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181225 |